Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

MLN9708

Home/Tag:MLN9708
23 09, 2015

Update on ixazomib

Tags: , , , |4 Comments

Don't sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda's oral proteasome inhibitor (MLN9708) at this year's ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015. Ixazomib is

8 03, 2015

Experts discuss new drugs likely to be approved by FDA

Tags: , , |0 Comments

OncLive.com posted a six member panel discussion about the two experimental drugs most likely to be approved next by the FDA: elotuzumab and ixazomib (MLN9708). The impressive group of panelists included doctors James R. Berenson, Sundar Jagannath, Shaji Kumar, Sagar Lonial, Keith K. Stewart and Jeffrey A. Zonder.  Here's a write-up about the exchange, along

31 10, 2014

Pat’s myeloma therapy plan

Tags: , , , , |10 Comments

Thank God pomalidomide is working for me!  But what do we do once it's not?  Dr. Roy and I had a chance to discuss that on Monday. First the good news.  Dr. Roy's gut feeling is that POM should work well for quite some time.  And statistics back him up.  Patients that respond like I

28 09, 2014

Which new myeloma drug will the FDA approve next?

Tags: , , , , |7 Comments

There are a half dozen experimental anti-myeloma drugs nearing the end of the research pipeline.  Which is most likely to be approved and when? A biologic immunotherapy drug like elotuzumab or daratumumab?  Millennium's new oral proteasome inhibitor, MLN9708? Although it only works well when combined with another drug like Revlimid, elotuzumab is the farthest along. 

28 12, 2013

Best of ASH13 (Part One)

Tags: , , , |5 Comments

It's time.  Christmas is behind us in the rear view mirror.  New Years is fast approaching.  And most of us should be recovered from our ASH hangovers!  Not literal hangovers from drinking Hurricanes at Pat O'Briens... No, I'm referencing the hangover from data overload left by over 800 myeloma related abstracts presented at this year's

3 09, 2013

September is Blood Cancer Awareness Month

Tags: , , , , , , , , |2 Comments

March is Multiple Myeloma Awareness Month.  Do we really need another?  Read this and you tell me! As I greeted support group members arriving before last month's meeting, an older couple that I didn't recognize introduced themselves and headed inside.  "We saw the announcement in the paper." The woman proudly announced loudly. "Are you the

6 01, 2013

Amyloidosis research picking-up steam

Tags: , , |0 Comments

Before shifting our focus to amyloidosis, I wanted to remind you that I have updated my December 28th post, in which I project how much longer a myeloma patient can expect to live once he or she has access to Kyprolis, pomalidomide and MLN9708.  You may want to revisit that one. There was quite a

29 12, 2012

Reality Check: How much longer might new therapies be expected to keep us alive?

Tags: , , , |14 Comments

OK.  Let's get real.  Readers are asking, "How long will access to the new myeloma therapies featured at ASH help me live? Tricky question.  Answering is like trying to hit a moving target.  Complicating things are combination therapies.  Even after a new myeloma drug is approved, experts still won't know how combining the new drug

21 12, 2012

If researchers can catch a break, many of us will live longer–a lot longer

Tags: , , , , , , |10 Comments

Significant news on the immunotherapy front.  A small bio-pharmaceutical company, Gliknik, put out a press release yesterday about their immunomodulator, post SCT study results that were presented at last week at ASH. Two things of note.  First, this is another University of Pennsylvania hosted study.  If you recall, Penn researchers administered the risky, yet highly

10 11, 2012

Dr. Ken Anderson discusses potential of combination therapies

Tags: , , , , , |9 Comments

Enough about me!  Here's an excerpt I saved from earlier this week on OncLive.com, featuring an interview with Dana-Farber's Dr. Ken Anderson: Overcoming Genetic Transformation in Multiple Myeloma Bonnie Gillis - OriginallyPublished Online: Tuesday, November 6, 2012 The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, Kenneth C.

25 09, 2012

Is it “all about the money?” Depends how you spin it…

Tags: , , , , |4 Comments

In case you missed it, the U.S. Food and Drug Administration has set a date for an advisory committee meeting to review the company’s application for approval of pomalidomide:  November 8th of this year. The agency is expected to make a decision about pomalidomide’s (New trade name, Actimid) application sometime early in February, 2013. Pomalidomide

15 09, 2012

Multiple Myeloma News & Notes

Tags: , , , , , , , |9 Comments

The Multiple Myeloma Research Consortium (MMRC) sent me a press release, touting the fact that, "The MMRC has opened more than 40 Phase I and Phase II clinical trials of both novel compounds and combination approaches that are thought to be active against high-priority targets." Impressive!  The group has backed studies involving elotuzumab, Millennium's oral

13 08, 2012

Multiple myeloma. What a ridiculous name!

Tags: , , |8 Comments

Yesterday I passed-along the new name that was selected for Millennium's experimental proteasome inhibitor, MLN9708:  ixazomib Is "ixazomib" a good choice?  Who knows? But I will suggest a name that isn't very good:  multiple myeloma. Isn't very good?  IT STINKS! I'm an educated guy.  A former business owner and teacher, I have a Masters degree--yet

12 08, 2012

Millennium Pharmaceutical’s MLN9708 has a name: ixazomib

Tags: , , , |0 Comments

Remember this name: ixazomib (ix az' oh mib) Originally dubbed MLN9708, Millennium Pharmaceutical's experimental proteasome inhibitor has as much potential to help patients as any new anti-myeloma drug in the research pipeline. So don’t you think that it deserved a name? To clarify, this isn’t the new drug’s trade name. Think about Onyx’s new proteasome

14 12, 2011

Great news for Velcade users who can’t stand needles…

Tags: , , , |4 Comments

Here is information about Millennium's new, oral proteasome inhibitor, MLN9708.  Looks like they are making good progress... Presentations at ASH Highlight results of Studies with MLN9708, First Oral Proteasome Inhibitorin Early Stage Clinical Trials in Multiple Myeloma CAMBRIDGE, Mass., Dec 13, 2011 Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited